Breast Neoplasms  >>  Ontruzant (trastuzumab-dttb)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ontruzant (trastuzumab-dttb) / Samsung, AffaMed Therap, Mundipharma, Organon
NCT02149524 / 2013-004172-35: A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

Checkmark Longest follow-up data in patients with HER2-positive early or locally advanced breast cancer
Dec 2021 - Dec 2021: Longest follow-up data in patients with HER2-positive early or locally advanced breast cancer
Checkmark Four-year follow-up results from P3 study at ASCO 2020
May 2020 - May 2020: Four-year follow-up results from P3 study at ASCO 2020
Completed
3
875
RoW
Herceptin (trastuzuamb), Herceptin, SB3 (proposed trastuzumab biosimilar)
Samsung Bioepis Co., Ltd.
HER2 Positive Early or Locally Advanced Breast Cancer
03/16
02/17

Download Options